

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY, DOCKET NO.	CONFIRMATION NO.
10/573,724	03/26/2007	Victor Anomah Ngu	133059-01US	2192
50659 Thomas Moga	7590 02/19/2008		EXAM	INER
Butzel Long	NEOT	SNYDER, STUART		
STONERIDGE WEST 41000 WOODWARD AVENUE			ART UNIT	PAPER NUMBER
BLOOMFIELD HILLS, MI 48304			1648	
			NOTIFICATION DATE	DELIVERY MODE
			02/19/2008	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ball@butzel.com patent@butzel.com burns@butzel.com

		Application No.	Applicant(s)			
Office Action Summary			NGU, VICTOR ANOMAH			
		10/573,724 Examiner	Art Unit			
	•		1648			
	The MAILING DATE of this communication app	Stuart W. Snyder	<del></del>			
Period fo		,				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DAISING OF MAILING OF MAI	ATE OF THIS COMMUNICATI 36(a). In no event, however, may a reply be vill apply and will expire SIX (6) MONTHS fr cause the application to become ABANDO	ON. e timely filed rom the mailing date of this communication. DNED (35 U.S.C. § 133).			
Status						
1)⊠	Responsive to communication(s) filed on 28 M	arch 2006.	•			
2a) <u></u> ☐	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11,	453 O.G. 213.			
Disposit	ion of Claims					
5) 6) 7)	Claim(s) <u>1-29</u> is/are pending in the application.  4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed.  Claim(s) is/are rejected.  Claim(s) is/are objected to.  Claim(s) <u>1-29</u> are subject to restriction and/or expressions.	vn from consideration.				
Applicat	ion Papers					
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Examine	epted or b) objected to by the drawing(s) be held in abeyance. Sion is required if the drawing(s) is	See 37 CFR 1.85(a). objected to. See 37 CFR 1.121(d).			
Priority (	under 35 U.S.C. § 119					
a)	Acknowledgment is made of a claim for foreign  All b) Some * c) None of:  1. Certified copies of the priority documents  2. Certified copies of the priority documents  3. Copies of the certified copies of the priority application from the International Bureau  See the attached detailed Office action for a list	s have been received. s have been received in Applic rity documents have been rece u (PCT Rule 17.2(a)).	ation No vived in this National Stage			
Attachmen	•	_				
2)  Notice 3)  Information	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	4)  Interview Summa Paper No(s)/Mail 5)  Notice of Informa 6)  Other:	l Date			

Application/Control Number:

10/573,724 Art Unit: 1648

## **DETAILED ACTION**

## Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claim(s) 1-12, drawn to a method of vaccine preparation including a lipid extracting step.
- Group II, claim(s) 12-20, drawn to drawn to a method of vaccine preparation including a lipid extracting step and mixing leukocytes with aqueous phase of lipid extraction.
- Group III, claim(s) 21, 26-27 and 29, drawn to a vaccine prepared by the method of Group I.
- Group IV, claim(s) 22 and 29, drawn to a method of use of the vaccine of Group III.
- Group V, claims 23-25, drawn to a vaccine prepared by the method of Group II.

The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The common technical feature of each of the groups is the step of lipid extraction of a pathogen to obtain a composition suitable for use as a vaccine. However, such practice is well-known in the art of vaccinology as evidenced

by the teachings of Eckels, et al. (Appl. Microbiol. 1970). As such the technical feature is not "special" within the meaning of PCT Rule 13.2.

2. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species are as follows:

Various biological fluids (see, for example, claim 2), various pathogens (see, for example, claims 3-6), various lipid extraction solvents (see, for example claims 11, 12, 14, 18 and 19),

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: All of the claims are generic.

10/573,724 Art Unit: 1648

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons:

The common technical feature of each of the groups is the step of lipid extraction of a pathogen to obtain a composition suitable for use as a vaccine. However, such practice is well-known in the art of vaccinology as evidenced by the teachings of Eckels, et al. (Appl. Microbiol. 1970). As such the technical feature is not "special" within the meaning of PCT Rule 13.2.

- A telephone call was made to Thomas T. Moga, Esq. on February 1, 2008 to request an oral election to the above restriction requirement, but did not result in an election being made.
- 4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds

10/573,724 Art Unit: 1648

one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart W. Snyder whose telephone number is (571) 272-9945. The examiner can normally be reached on 9:00 AM-5:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce R. Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MARY E. MOSHER, PH.D. PRIMARY EXAMINER Stuart W Snyder Examiner Art Unit 1648